Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors With or Without Chemotherapy

NCT05055908 is registered in ClinicalTrials.gov with Hunan Province Tumor Hospital as lead sponsor.

NCT NCT05055908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05055908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors With or Without Chemotherapy
Lead sponsor
Hunan Province Tumor Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
October 1, 2021
Completion date
September 14, 2027
Enrollment
12,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer